Wells Fargo
CAPR icon

Wells Fargo’s Capricor Therapeutics CAPR Stock Holding History

Wells Fargo’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.28M Buy
53,188
+31,764
+148% +$963K ﹤0.01% 3941
2026
Q1 		$651K Sell
21,424
-24,180
-53% -$644K ﹤0.01% 4002
2025
Q4 		$1.32M Buy
45,604
+5,610
+14% +$73.3K ﹤0.01% 3754
2025
Q3 		$288K Sell
39,994
-1,308
-3% -$9.63K ﹤0.01% 4711
2025
Q2 		$410K Sell
41,302
-15,821
-28% -$167K ﹤0.01% 4286
2025
Q1 		$542K Buy
57,123
+17,632
+45% +$245K ﹤0.01% 4037
2024
Q4 		$545K Sell
39,491
-4,641
-11% -$81.3K ﹤0.01% 4120
2024
Q3 		$671K Sell
44,132
-814
-2% -$4.03K ﹤0.01% 3806
2024
Q2 		$214K Buy
44,946
+12,384
+38% +$69.1K ﹤0.01% 4475
2024
Q1 		$221K Buy
32,562
+32,326
+13,697% +$156K ﹤0.01% 4408
2023
Q4 		$1.15K Buy
236
+48
+26% +$156 ﹤0.01% 6192
2023
Q3 		$643 Sell
188
-994
-84% -$5.59K ﹤0.01% 6307
2023
Q2 		$5.65K Buy
1,182
+7
+0.6% +$31 ﹤0.01% 6056
2023
Q1 		$4.96K Buy
1,175
+1,003
+583% +$4.32K ﹤0.01% 6059
2022
Q4 		$664 Buy
172
+10
+6% +$48 ﹤0.01% 6304
2022
Q3 		$1K Sell
162
-1
-0.6% -$5 ﹤0.01% 6292
2022
Q2 		$1K Sell
163
-986
-86% -$3.5K ﹤0.01% 6473
2022
Q1 		$4K Buy
1,149
+1
+0.1% +$4 ﹤0.01% 6511
2021
Q4 		$3K Buy
1,148
+1,008
+720% +$3.53K ﹤0.01% 6791
2021
Q3 		$1K Sell
140
-7
-5% -$32 ﹤0.01% 6664
2021
Q2 		$1K Buy
147
+14
+11% +$59 ﹤0.01% 6624
2021
Q1 		$1K Hold
133
– – ﹤0.01% 6689
2020
Q4 		$0 Buy
133
+12
+10% +$52 ﹤0.01% 6504
2020
Q3 		$1K Sell
121
-2,902
-96% -$16.9K ﹤0.01% 6184
2020
Q2 		$14K Buy
3,023
+3,000
+13,043% +$13.1K ﹤0.01% 5774
2020
Q1 		$0 Buy
+23
New +$32 ﹤0.01% 6215
2018
Q1 		– Sell
-3,530
Closed -$56K – 6365
2017
Q4 		$56K Hold
3,530
– – ﹤0.01% 5516
2017
Q3 		$107K Buy
+3,530
New +$42.3K ﹤0.01% 5205
2015
Q4 		– Sell
-1
Closed – – 6227
2015
Q3 		$0 Buy
+1
New +$45 ﹤0.01% 6211

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wells Fargo's CAPR Position: Q2 2026 in Review

Wells Fargo increased its Capricor Therapeutics (CAPR) stake by 148% in Q2 2026, buying an estimated $963K and bringing the position to 53,188 shares worth $1.28M. The position accounts for ﹤0.01% of the portfolio, ranked #3941.

Wells Fargo first reported a position in CAPR in Q3 2015 and has held it in 29 quarters since. The position peaked at $1.32M in Q4 2025. 170 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • Wells Fargo held 53,188 shares of Capricor Therapeutics worth $1.28M as of Q2 2026.
  • Wells Fargo bought 31,764 Capricor Therapeutics shares in Q2 2026, an estimated $963K.
  • Capricor Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #3941 holding.
  • Wells Fargo first reported a position in Capricor Therapeutics in Q3 2015 and has held it in 29 quarters since.
  • Wells Fargo's Capricor Therapeutics position peaked at $1.32M in Q4 2025.
  • 170 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.